Late Diagnosis of Primary Hyperoxaluria Type 1 After Kidney Transplant
Authors:
- Sabrina Maria Araujo SobreiraSSSabrina Maria Araujo Sobreira
- Beatriz de Oliveira NeriBNBeatriz de Oliveira Neri
- Vanessa Gurgel AdeodatoVAVanessa Gurgel Adeodato
- Arthur Holanda DantasADArthur Holanda Dantas
- Sebastiao Alves Sobreira NetoSNSebastiao Alves Sobreira Neto
- André Costa TeixeiraATAndré Costa Teixeira
- Ronaldo de Matos EsmeraldoRERonaldo de Matos Esmeraldo
Open Access
- 28 April 2026
- journal article
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
Abstract
Primary hyperoxaluria type 1 is a rare and often unrecognized cause of renal allograft dysfunction and loss, particularly when renal disease is attributed to recurrent nephrolithiasis. We report the case of a 62-year-old woman with a history of bilateral nephrolithiasis and prolonged use of anti-inflammatory drugs who underwent kidney transplantation with immediate graft function and an initially favorable course. After an extended period of stability, late and progressive graft dysfunction occurred. Allograft biopsy demonstrated tubular injury associated with extensive calcium oxalate crystal deposition, suggesting oxalosis. Serum oxalate was 18.6 µmol/L, and urinary oxalate was 94.9 mg/24 h. Genotyping identified a homozygous pathogenic variant in the AGXT gene, confirming the diagnosis of primary hyperoxaluria type 1. Review of the medical history revealed nephrocalcinosis in native kidneys, and family screening identified a sibling with nephrolithiasis. Pharmacological-dose pyridoxine was initiated as first-line therapy based on the responsive genotype, followed by RNA interference therapy with lumasiran due to the high risk of graft loss, resulting in initial stabilization of graft function. This report emphasizes that primary hyperoxaluria type 1 should be considered in transplant recipients with a history of nephrolithiasis, even in adulthood, and that post-transplant identification has direct implications for graft prognosis, therapeutic approach, and family screening, highlighting the need for metabolic and genetic investigation in selected cases before transplantation.Keywords
This publication has 14 references indexed in Scilit:
- Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K Working Group of the ERA and ESPNNephrology Dialysis Transplantation, 2025
- Diagnosis and management of primary hyperoxalurias: best practicesPediatric Nephrology, 2024
- Lumasiran, Isolated Kidney Transplantation, and Continued VigilanceNew England Journal of Medicine, 2024
- A clinical screening algorithm for primary hyperoxaluria type 1 in adults on dialysisNephrology Dialysis Transplantation, 2023
- Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEuropeNature Reviews Nephrology, 2023
- Primary hyperoxaluria type 1: novel therapies at a glanceClinical Kidney Journal, 2022
- Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1New England Journal of Medicine, 2021
- Primary HyperoxaluriaNew England Journal of Medicine, 2013
- Update on Oxalate Crystal DiseaseCurrent Rheumatology Reports, 2013
- Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsAmerican Journal of Transplantation, 2009